NCT03209518View on ClinicalTrials.gov

"Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in Premenopausal Breast Cancer"

CompletedOBSERVATIONAL
Enrollment

312

Participants

Timeline

Start Date

March 18, 2016

Primary Completion Date

October 10, 2018

Study Completion Date

October 10, 2018

Conditions
Premenopausal Breast Cancer
Interventions
DRUG

Leuprorelin acetate

Leuplin PRO for Injection Kit 22.5 mg

Trial Locations (1)

Unknown

Takeda selected site, Tokyo

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT03209518 - "Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in Premenopausal Breast Cancer" | Biotech Hunter | Biotech Hunter